Sarah A. Kent

Sarah A. Kent

Auto-generated profile, based on publicly available information

Sarah A. Kent

UK Dementia Research Institute at The University of Edinburgh, Edinburgh, UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2020 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
SKSarah A. Kent
Sarah A. Kent
TSTara L. Spires-Jones
Tara L. Spires-Jones
CDClaire S. Durrant
Claire S. Durrant
Tau and amyloid beta (Aβ) are the prime suspects for driving pathology in Alzheimer’s disease (AD) and, as such, have become the focus of therapeutic development. Recent research, however, shows that these proteins have been highly conserved throughout evolution and may have crucial, physiological roles. Such functions may be lost during AD progression or be unintentionally disrupted by tau- or Aβ-targeting therapies. Tau has been revealed to be more than a simple stabiliser of microtubules, reported to play a role in a range of biological processes including myelination, glucose metabolism, axonal transport, microtubule dynamics, iron homeostasis, neurogenesis, motor function, learning and memory, neuronal excitability, and DNA protection. Aβ is similarly multifunctional, and is proposed to regulate learning and memory, angiogenesis, neurogenesis, repair leaks in the blood–brain barrier, promote recovery from injury, and act as an antimicrobial peptide and tumour suppressor. This review will discuss potential physiological roles of tau and Aβ, highlighting how changes to these functions may contribute to pathology, as well as the implications for therapeutic development. We propose that a balanced consideration of both the physiological and pathological roles of tau and Aβ will be essential for the design of safe and effective therapeutics.

8 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
IMIrene Molina-Gonzalez
Irene Molina-Gonzalez
RHRebecca K. Holloway
Rebecca K. Holloway
ZJZoeb Jiwaji
Zoeb Jiwaji
ODOwen Dando
Owen Dando
SKSarah A. Kent
Sarah A. Kent
VMVeronique Miron
Veronique Miron
Failed regeneration of myelin around neuronal axons following central nervous system damage contributes to nerve dysfunction and clinical decline in various neurological conditions, for which there is an unmet therapeutic demand. Here, we show that interaction between glial cells – astrocytes and mature myelin-forming oligodendrocytes – is a determinant of remyelination. Using in vivo/ ex vivo/ in vitro rodent models, unbiased RNA sequencing, functional manipulation, and human brain lesion analyses, we discover that astrocytes support the survival of regenerating oligodendrocytes, via downregulation of the Nrf2 pathway associated with increased astrocytic cholesterol biosynthesis pathway activation. Remyelination fails following sustained astrocytic Nrf2 activation in focally-lesioned male mice yet is restored by either cholesterol biosynthesis/efflux stimulation, or Nrf2 inhibition using the existing therapeutic Luteolin. We identify that astrocyte-oligodendrocyte interaction regulates remyelination, and reveal a drug strategy for central nervous system regeneration centred on targeting this interaction.

14 July 2023 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
SKSarah A. Kent
Sarah A. Kent
VMVeronique Miron
Veronique Miron